

Resource Summary Report

Generated by [NIF](#) on Aug 13, 2026

4E-BP1 Antibody

RRID:AB_331692

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9452, RRID:AB_331692

Antibody Information

URL: http://antibodyregistry.org/AB_331692

Proper Citation: Cell Signaling Technology Cat# 9452, RRID:AB_331692

Target Antigen: 4E-BP1

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation: AB_10693791, AB_823410. Info: Used By NYUIHC-582.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: 4E-BP1 Antibody

Description: This polyclonal targets 4E-BP1

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_331692

Vendor: Cell Signaling Technology

Catalog Number: 9452

Alternative Catalog Numbers: 9452S, 9452L

Record Creation Time: 20250820T021230+0000

Record Last Update: 20250820T125839+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for 4E-BP1 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 102 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Hsieh CW, et al. (2026) Graded activation of the CLEAR network through mTORC1 suppression on cargo-harboring lysosomes. Cell reports, 45(4), 117228.

Lara Castillo NA, et al. (2026) Exercise beneficially reshapes fasted rat skeletal muscle involving the combined action of β -hydroxybutyrate and palmitoleic acid. American journal of physiology. Cell physiology, 330(4), C1006.

Powers J, et al. (2026) eIF4G2-Dependent Translation Restrains Pancreatic Cancer Progression. Cancer research.

Choi YK, et al. (2026) The REDD1-NF- κ B-miRNAs-eNOS/SIRT1 axis mediates obesity-induced endothelial cell senescence and hypertension. Nature communications, 17(1).

Yamauchi T, et al. (2026) Valine availability controls oncogenic cell-cycle progression through translation of D-type cyclins. Biochemical pharmacology, 246, 117706.

Li G, et al. (2026) Mitochondrial VHL rewires cell metabolism in hypoxia. Cell metabolism, 38(1), 174.

Bakhmet EI, et al. (2026) PCBP1 orchestrates amino acid metabolism burst during the naïve-to-primed pluripotency transition. Stem cell reports, 21(7), 102950.

Lin Y, et al. (2026) Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies. eLife, 15.

Li Y, et al. (2025) Lactylation of mTOR enhances autophagy in skeletal muscle during exercise. Cell chemical biology, 32(11), 1367.

Jasani N, et al. (2025) PHGDH Induction by MAPK Is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability. *Cancer research*, 85(2), 314.

Nishikubo K, et al. (2025) Sustained reductions in valine and isoleucine mediate anti-cancer pharmacological effects of inhibiting amino acid transporter LAT1 in cancer cells. *Cancer & metabolism*, 13(1), 46.

Kitab B, et al. (2025) Ribonucleotide reductase subunit M2 mediates the mTOR pathway to recruit furin endoprotease and promote maturation of dengue virus. *iScience*, 28(12), 113998.

Zhang F, et al. (2025) RHEB neddylation by the UBE2F-SAG axis enhances mTORC1 activity and aggravates liver tumorigenesis. *The EMBO journal*, 44(4), 1185.

Tiburcio PDB, et al. (2025) Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor. *Cell reports. Medicine*, 6(5), 102133.

Thalalla Gamage S, et al. (2025) Transfer RNA acetylation regulates in vivo mammalian stress signaling. *Science advances*, 11(12), eads2923.

Budagyan K, et al. (2025) KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation. *Cell reports*, 44(4), 115444.

Remy D, et al. (2024) TFEB triggers a matrix degradation and invasion program in triple-negative breast cancer cells upon mTORC1 repression. *Developmental cell*.

Tiburcio PDB, et al. (2024) Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor. *bioRxiv : the preprint server for biology*.

Zhu M, et al. (2024) PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer. *Cell metabolism*, 36(8), 1711.

Turgu B, et al. (2023) The HACE1 E3 ligase mediates RAC1-dependent control of mTOR signaling complexes. *EMBO reports*, 24(12), e56815.